ALCLS Stock Overview
A clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Cellectis S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.59 |
| 52 Week High | €3.44 |
| 52 Week Low | €1.53 |
| Beta | 3.15 |
| 1 Month Change | -8.30% |
| 3 Month Change | -23.00% |
| 1 Year Change | -45.13% |
| 3 Year Change | -78.97% |
| 5 Year Change | -90.74% |
| Change since IPO | -89.23% |
Recent News & Updates
Recent updates
A Look At The Intrinsic Value Of Cellectis S.A. (EPA:ALCLS)
Feb 07
Analyst Forecasts Just Became More Bearish On Cellectis S.A. (EPA:ALCLS)
Aug 09Is Cellectis (EPA:ALCLS) Using Too Much Debt?
Dec 14Analysts' Revenue Estimates For Cellectis S.A. (EPA:ALCLS) Are Surging Higher
Aug 07We Think Some Shareholders May Hesitate To Increase Cellectis S.A.'s (EPA:ALCLS) CEO Compensation
May 26Is Cellectis (EPA:ALCLS) Using Debt Sensibly?
May 17These Analysts Think Cellectis S.A.'s (EPA:ALCLS) Sales Are Under Threat
Mar 08Cellectis (EPA:ALCLS) Is In A Strong Position To Grow Its Business
Feb 16Shareholder Returns
| ALCLS | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -14.5% | -5.2% | -0.4% |
| 1Y | -45.1% | -30.2% | -4.1% |
Return vs Industry: ALCLS underperformed the French Biotechs industry which returned -29.6% over the past year.
Return vs Market: ALCLS underperformed the French Market which returned -4% over the past year.
Price Volatility
| ALCLS volatility | |
|---|---|
| ALCLS Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.6% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALCLS has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: ALCLS's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 219 | Andre Choulika | www.cellectis.com |
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin’s lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Cellectis S.A. Fundamentals Summary
| ALCLS fundamental statistics | |
|---|---|
| Market cap | €159.15m |
| Earnings (TTM) | -€80.43m |
| Revenue (TTM) | €34.32m |
4.6x
P/S Ratio-2.0x
P/E RatioIs ALCLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALCLS income statement (TTM) | |
|---|---|
| Revenue | US$36.04m |
| Cost of Revenue | US$737.00k |
| Gross Profit | US$35.31m |
| Other Expenses | US$119.78m |
| Earnings | -US$84.48m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.84 |
| Gross Margin | 97.96% |
| Net Profit Margin | -234.39% |
| Debt/Equity Ratio | 34.5% |
How did ALCLS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/17 05:27 |
| End of Day Share Price | 2024/12/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cellectis S.A. is covered by 21 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Madhu Kumar | Baird |
| Huidong Wang | Barclays |